Rebyota is a fecal microbiota product used for the prevention of recurrence of Clostridioides difficile infection (CDI).
It is manufactured from human fecal matter donated by screened individuals.
It is manufactured from human fecal matter and may carry a risk of transmitting infectious agents.
It facilitates the restoration of the gut flora to prevent further episodes of Clostridioides difficile infection.
It is administered rectally 24 to 72 hours after the last dose of antibiotics for the treatment of recurrent CDI.
It is not indicated for treatment of CDI.
Rebyota has not been studied in patients below 18 years of age.
It is used for the prevention of recurrent Clostridioides difficile infection (CDI) in individuals 18 years of age and older, following antibiotic treatment for recurrent CDI.
Oral antibiotics should not taken for up to 8 weeks after receiving this drug..
It may contain food allergens, although the potential for the product to cause adverse reactions due to food allergens is unknown.
Ot is administered by rectum.
150 mL administered rectally as a single dose.
Side effects;
stomach pain
diarrhea,
bloating,
gas, and nausea.
It should be stored in an ultracold freezer (-60˚C to -90˚C or -76˚F to -130˚F). Alternatively, store in a refrigerator (2˚C to 8˚C or 36˚F to 46˚F) for up to 5 days (including thaw time).